Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.
OPKO Completes Acquisition of Bio-Reference Laboratories.
OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016 more »
OPKO Presents Additional Data on RAYALDEE(R) at National Kidney Foundation Spring Clinical Meetings 2016 more »
FDA Accepts Resubmission of New Drug Application for RAYALDEE® more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
Former shareholders of Bio-Reference Laboratories, Inc. that have questions related to the exchange of BRLI shares to OPK shares, please contact our exchange agent, American Stock Transfer & Trust Company, LLC, toll free at (877) 248-6417 or (718) 921-8317.